Cite
HARVARD Citation
Goss, C. et al. (2020). An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1. ERJ open research. 6 (4), p. . [Online].